Patients perceive tonsil cancer as a strike at psycho-socially "vital organs"

Danish Medical Journal

Volumn 59, Issue 9, 2012, Pages

  Mortensen, Gitte Lee ^a   Paaske, Peter Bertram ^b  

^a AnthroConsult   (Denmark)

^b ENT (Ear nosethroat) Clinic   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; EATING DISORDER; FATIGUE; FEMALE; HUMAN; INTERVIEW; MALE; MENTAL COMPLIANCE; NAUSEA; PAIN; QUALITY OF LIFE; SPEECH DISORDER; TONSIL CANCER; TOOTH DISEASE; XEROSTOMIA; EATING; HEARING DISORDER; JAW; MIDDLE AGED; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; PSYCHOLOGICAL ASPECT; RADIOTHERAPY; SOCIAL PARTICIPATION; TIME; TONGUE; TONSIL TUMOR;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; EATING; FATIGUE; FEMALE; HEARING DISORDERS; HUMANS; INTERVIEWS AS TOPIC; JAW; MALE; MIDDLE AGED; NAUSEA; PAIN; POSTOPERATIVE COMPLICATIONS; QUALITY OF LIFE; RADIOTHERAPY; SOCIAL PARTICIPATION; SPEECH DISORDERS; TIME FACTORS; TONGUE; TONSILLAR NEOPLASMS; TOOTH DISEASES; XEROSTOMIA;

EID: 84873262918     PISSN: None     EISSN: 22451919     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Johansen J, Lassen P. Nationale retningslinjer for udredning, behandling, rehabilitering og kontrolforløb for patienter med pharynx-og larynxcancer i Danmark. Dansk Selskab for Hoved-og Hals Onkologi (DSHHO) og Den Danske Hoved-Hals Cancer Gruppe/Danish Head and Neck Cancer Group (DAHANCA) 2011:8-9.
2. Dayyani F, Etzel CJ, Liu M et al. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol 2010;2:15.
3. D'Souza G, Dempsey A. The role of HPV in head and neck cancer and review of the HPV vaccine. Prev Med 2011;53:5-11.
4. Danish Cancer Registry 2009. www.sst.dk/publ/Publ2010/DOKU/Registre/ Cancerregisteret2009.pdf (1 May 2012).
5. Lassen P. The role of human papillomavirus in head and neck cancer and the impact on radiotherapy outcome. Radiother Oncol 2010;95:371-80.
6. Hartwig S, Syrjanen S, Kominiak-Felden G et al. Estimation of the epidemiological burden of human papillomavirus-related cancers and nonmalignant diseases in men in Europe: a review. BMC Cancer 2012;12:30.
7. Näsman A, Attner P, Hammarstedt L. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: An epidemic of viral-induced carcinoma? Int J Cancer 2009;125:362-6.
8. Vissink A, Jansma J, Spijkervet FK et al. Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med 2003;14:199-212.
9. Lydiatt WM, Moran J, Burke WJ. A review of depression in the head and neck cancer patient. Clin Adv Hematol Oncol 2009;7:397-403.
10. Rogers SN, Ahad SA, Murphy AP. A structured review and theme analysis of papers published on 'quality of life' in head and neck cancer: 2000-2005. J Oral Oncol 2007;43:843-68.
11. Röing M, Hirsch JM, Holmström I et al. Making new meanings of being in the world after treatment for oral cancer. Qual Health Res 2009;19:1076-86.
12. Semple CJ, Dunwoody, L, Kernohan WG et al. Changes to patients' life style patterns following treatment for head and neck cancer. JAN 2008;63:85-93.
13. Kleinman A. Writing at the margin: discourse between anthropology and medicine. Berkeley CA, University of California Press 1997.
14. Mogensen HO. Det narrative omdrejningspunkt. I: Risør MB, Mogensen H, Paarup B et al, eds. Narrativer. Tidsskrift for forskning i Sygdom og Samfund 2005;2:5-11.
15. Spradley JP. The ethnographic interview. New York: Holt, Rinehart and Winston, 1979.
16. Høirup Petersen S, Feldinger B, Jessen N et al. Patient experienced side effects and adverse events after cancer treatment-patient initiated research. Clin P Health 2011;1:5-8.
17. McQuestion M, Fitch M, Howell, D. The changed meaning of food: Physical, social and emotional loss for patients having received radiation treatment for head and neck cancer. Eur J Oncol Nurs 2011;15:145-51.
18. Hillman RJ, Giuliano AR, Palefsky JM et al. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. Clin Vaccine Immunol 2012;19:261-7.
19. McCormack PL, Joura EA. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women. Drugs. 2010;70:2449-74.
20. Centers for Disease Control and Prevention. Recommendations on the use of quadrivalent human papillomavirus vaccine in males-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011;60:1705-8.